New drug HBM7020 enters first human tests for lupus and arthritis
NCT ID NCT07649265
First seen Jun 17, 2026 · Last updated Jun 19, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called HBM7020 in 63 people. It starts with healthy volunteers to check safety, then moves to patients with autoimmune diseases like lupus, rheumatoid arthritis, scleroderma, and Sjögren's disease. The goal is to see if the drug is safe and how the body processes it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HBM7020 (a drug given through an IV infusion)
What this could lead to
If it works, this could point toward a new treatment for autoimmune diseases like lupus, rheumatoid arthritis, and scleroderma.
What could go wrong
This is a very early, small Phase 1 trial focused on safety, not effectiveness. It may fail to show benefit or have side effects like infusion reactions or infections.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.